文献速递泌尿生殖与妇科肿瘤放疗

Gleason评分10分前列腺腺癌患者的临床结局:多机构联盟研究结果

Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-04-05

该多机构联盟研究纳入2000至2013年间112例活检确诊Gleason评分10分前列腺腺癌患者,分别接受根治性前列腺切除术(26例)、外照射放疗(48例)或外照射放疗联合近距离放疗推量(38例)。中位随访4.9年,倾向评分调整后5年总生存率分别为80%、73%和83%,5年前列腺癌特异性生存率分别为87%、75%和94%;外照射联合近距离放疗推量组远处无转移生存优于外照射组(HR 0.4,95%CI 0.1-0.99,P=.048)。

要点

  • 活检确诊Gleason评分10分前列腺癌患者接受根治性前列腺切除术、外照射放疗或外照射联合近距离放疗推量,倾向评分调整后5年总生存率分别为80%、73%和83%。
  • 外照射联合近距离放疗推量组5年前列腺癌特异性生存率为94%,高于根治性前列腺切除术组的87%和外照射放疗组的75%。
  • 外照射联合近距离放疗推量组远处无转移生存优于外照射放疗组(HR 0.4,95%CI 0.1-0.99,P=.048),与根治性前列腺切除术组比较趋势更优但未达统计学显著(HR 0.3,95%CI 0.1-1.06,P=.06)。

核心结论

  • 据作者所知,这是迄今报告的最大样本量的活检确诊Gleason评分10分前列腺腺癌临床结局系列。
  • 这些数据为医生和患者提供了有用的预后基准信息。
  • 超过50%的患者在治疗后5年仍无全身性疾病,因此有必要进行以治愈为目的的积极治疗。

研究设计与样本

  • 多机构联盟研究,纳入2000至2013年间112例活检确诊Gleason评分10分前列腺腺癌患者。
  • 患者分别接受根治性前列腺切除术(n=26)、外照射放疗(n=48)或外照射放疗联合近距离放疗推量(n=38)。
  • 采用倾向评分作为协变量进行比较分析,并以逆概率治疗加权控制混杂因素。
  • 采用Kaplan-Meier法估算总生存、前列腺癌特异性生存和远处无转移生存。

主要发现

  • 总体中位随访时间为4.9年(根治性前列腺切除术组3.9年,外照射放疗组4.8年,外照射联合近距离放疗推量组5.7年)。
  • 外照射放疗组接受 upfront 雄激素剥夺治疗的患者比例显著多于外照射联合近距离放疗推量组(98% vs 79%,χ2检验P<.01),但两组持续时间相似(中位24个月 vs 22.5个月)。
  • 根治性前列腺切除术组中34%接受术后外照射放疗,35%接受新辅助全身治疗。
  • 倾向评分调整后5年总生存率:根治性前列腺切除术组80%,外照射放疗组73%,外照射联合近距离放疗推量组83%。
  • 倾向评分调整后5年前列腺癌特异性生存率:根治性前列腺切除术组87%,外照射放疗组75%,外照射联合近距离放疗推量组94%。

临床怎么用

  • 作者认为,对于活检确诊Gleason评分10分前列腺腺癌,有必要进行以治愈为目的的积极治疗,因为超过50%的患者在治疗后5年仍无全身性疾病。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Gleason score (GS) 10 disease is the most aggressive form of clinically localized prostate adenocarcinoma (PCa). The long-term clinical outcomes and overall prognosis of patients presenting with GS 10 PCa are largely unknown because of its rarity. METHODS AND MATERIALS: The study included 112 patients with biopsy-determined GS 10 PCa who received treatment with radical prostatectomy (RP, n = 26), external beam radiation therapy (EBRT, n = 48), or EBRT with a brachytherapy boost (EBRT-BT, n = 38) between 2000 and 2013. Propensity scores were included as covariates for comparative analysis. Overall survival, prostate cancer-specific survival, and distant metastasis-free survival (DMFS) were estimated by the Kaplan-Meier method with inverse probability of treatment weighting to control for confounding. RESULTS: The median follow-up period was 4.9 years overall (3.9 years for RP, 4.8 years for EBRT, and 5.7 years for EBRT-BT). Significantly more EBRT patients than EBRT-BT patients received upfront androgen deprivation therapy (98% vs 79%, P < .01 by χ2 test), though the durations were similar (median, 24 months vs 22.5 months). Of the RP patients, 34% received postoperative EBRT, and 35% received neoadjuvant systemic therapy. The propensity score-adjusted 5-year overall survival rate was 80% for the RP group, 73% for the EBRT group, and 83% for the EBRT-BT group. The corresponding adjusted 5-year prostate cancer-specific survival rates were 87%, 75%, and 94%, respectively. The EBRT-BT group trended toward superior DMFS when compared with the RP group (hazard ratio, 0.3; 95% confidence interval 0.1-1.06; P = .06) and had superior DMFS when compared with the EBRT group (hazard ratio, 0.4; 95% confidence interval 0.1-0.99; P = .048). CONCLUSIONS: To our knowledge, this is the largest series ever reported on the clinical outcomes of patients with biopsy-determined GS 10 PCa. These data provide useful prognostic benchmark information for physicians and patients. Aggressive therapy with curative intent is warranted, as >50% of patients remain free of systemic disease 5 years after treatment.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Sandler KA, Cook RR, Ciezki JP, et al. Clinical Outcomes for Patients With Gleason Score 10 Prostate Adenocarcinoma: Results From a Multi-institutional Consortium Study. Int J Radiat Oncol Biol Phys. 2018. PMID: 29976500. doi:10.1016/j.ijrobp.2018.03.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。